Mettler-Toledo International (NYSE:MTD) Releases Q2 2022 Earnings Guidance

Mettler-Toledo International (NYSE:MTDGet Rating) updated its second quarter 2022 earnings guidance on Thursday. The company provided EPS guidance of $8.70-$8.80 for the period, compared to the consensus EPS estimate of $8.80. The company issued revenue guidance of $989.06 million-$989.06 million, compared to the consensus revenue estimate of $946.77 million.Mettler-Toledo International also updated its FY 2022 guidance to $38.20-$38.50 EPS.

A number of analysts have recently commented on MTD shares. Robert W. Baird boosted their price objective on shares of Mettler-Toledo International from $1,531.00 to $1,595.00 in a research report on Friday, February 11th. StockNews.com initiated coverage on Mettler-Toledo International in a report on Thursday, March 31st. They set a buy rating on the stock. The Goldman Sachs Group downgraded shares of Mettler-Toledo International from a neutral rating to a sell rating and set a $1,240.00 price objective for the company. in a research report on Thursday, March 10th. Finally, Wells Fargo & Company raised shares of Mettler-Toledo International from an equal weight rating to an overweight rating and reduced their target price for the company from $1,600.00 to $1,410.00 in a research report on Monday, April 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $1,449.25.

NYSE:MTD opened at $1,194.52 on Thursday. Mettler-Toledo International has a fifty-two week low of $1,168.31 and a fifty-two week high of $1,714.75. The company has a 50 day simple moving average of $1,323.05 and a two-hundred day simple moving average of $1,445.12. The company has a market capitalization of $27.16 billion, a PE ratio of 35.08, a P/E/G ratio of 1.68 and a beta of 1.07. The company has a debt-to-equity ratio of 20.89, a quick ratio of 0.79 and a current ratio of 1.20.

Mettler-Toledo International (NYSE:MTDGet Rating) last released its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $7.87 earnings per share for the quarter, beating analysts’ consensus estimates of $7.32 by $0.55. The firm had revenue of $897.80 million for the quarter, compared to analyst estimates of $868.08 million. Mettler-Toledo International had a net margin of 20.82% and a return on equity of 540.97%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm earned $6.56 earnings per share. Research analysts predict that Mettler-Toledo International will post 38.35 EPS for the current year.

In related news, Director Olivier A. Filliol sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, March 2nd. The shares were sold at an average price of $1,390.27, for a total transaction of $17,378,375.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Shawn Vadala sold 1,846 shares of the business’s stock in a transaction dated Friday, February 25th. The stock was sold at an average price of $1,445.00, for a total transaction of $2,667,470.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,594 shares of company stock worth $40,548,884. 2.80% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Mettler-Toledo International by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 2,534,104 shares of the medical instruments supplier’s stock worth $3,479,806,000 after purchasing an additional 17,826 shares during the period. Invesco Ltd. raised its position in Mettler-Toledo International by 7.9% in the first quarter. Invesco Ltd. now owns 224,404 shares of the medical instruments supplier’s stock worth $308,147,000 after acquiring an additional 16,439 shares during the period. Barclays PLC boosted its stake in Mettler-Toledo International by 8.2% in the fourth quarter. Barclays PLC now owns 205,188 shares of the medical instruments supplier’s stock valued at $348,247,000 after acquiring an additional 15,593 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Mettler-Toledo International by 3.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 126,516 shares of the medical instruments supplier’s stock valued at $173,731,000 after acquiring an additional 3,969 shares during the period. Finally, Deutsche Bank AG increased its stake in shares of Mettler-Toledo International by 3.0% during the 4th quarter. Deutsche Bank AG now owns 93,374 shares of the medical instruments supplier’s stock worth $158,475,000 after purchasing an additional 2,737 shares during the last quarter. 93.88% of the stock is currently owned by hedge funds and other institutional investors.

About Mettler-Toledo International (Get Rating)

Mettler-Toledo International Inc engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments.

Further Reading

Earnings History and Estimates for Mettler-Toledo International (NYSE:MTD)

Receive News & Ratings for Mettler-Toledo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mettler-Toledo International and related companies with MarketBeat.com's FREE daily email newsletter.